Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service

QIAGEN's QuantiFERON®-TB Access development program gains recognition from United Nations initiative for health innovation


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that QuantiFERON®-TB Access, a new solution under development for diagnosis of latent tuberculosis (TB) infection in low-resource regions with a high disease burden of tuberculosis, will be recognized by the Joint United Nations Programme on HIV/AIDS (UNAIDS) at the organization's Health Innovation Exchange from May 21-23 in Geneva, Switzerland. The event will be held during the World Health Assembly and brings together ministers of health, nonprofits and industry to spotlight innovations with potential to change the world's health landscape and benefit sustainable development.

QuantiFERON-TB Access (QFT® Access) is a proprietary new test designed to advance tuberculosis control in areas with limited infrastructure, including countries in Asia, Africa and Latin America. The World Health Organization (WHO) has classified 30 countries in these regions as high-burden, representing an estimated 85% of the global TB burden. QFT Access pairs highly sensitive digital detection with a complete workflow created to deliver cost-efficient results quickly and with unmatched simplicity. It eliminates the need for an extensive laboratory infrastructure while providing best-in-class QuantiFERON technology. Clinical trials are being conducted in 2019, and commercialization of QFT Access is expected to begin in 2020.

"We are pleased that UNAIDS selected QuantiFERON-TB Access for recognition at the Health Innovation Exchange. QIAGEN's drive to develop QFT Access springs from the need for a modern, accurate test for TB infection screening in areas where the disease burden is high but resources and infrastructure are scarce," said Thierry Bernard, Senior Vice President, Head of the Molecular Diagnostics Business Area at QIAGEN. "QFT Access builds on the success of QuantiFERON®-TB Gold Plus, the modern gold standard for detection of latent TB infection. We have created a field-friendly Sample to Insight solution using a simple test to reduce costs and labor and avoid the need for cold chain, a computer or continuous power supply."

QIAGEN is developing QuantiFERON-TB Access in partnership with Ellume, an Australian developer of digitally-enabled diagnostics. QFT Access is a single visit, single tube test using 1 ml blood test that is scalable. It is not impacted by BCG vaccination, which can cause false-positive results with the tuberculin skin test used in many low-resource settings. QFT Access requires less than five minutes of hands-on time from a technician or phlebotomist. The result can be digitally displayed on a portable device or, optionally, connected to a computer for printout or electronic transmission. The system does not require maintenance or calibration, and it minimizes the impact of power loss or dust.

Please find full press release here.

###


These press releases may also interest you

at 10:56
After months of build-out and testing in the Lower Saint Lawrence, Videotron announces the official launch of its mobile network in Rimouski and 12 neighbouring municipalities.1 Starting today, local residents can enjoy the best customer experience...

at 10:55
Humanetics Corporation (Humanetics) announced today that it has entered into a definitive agreement with DSM Nutritional Products Ltd of Kaiseraugst Switzerland to acquire all of DSM's assets related to the manufacture of the active pharmaceutical...

at 10:53
Vuzix® Corporation , ("Vuzix" or, the "Company"), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, and Librestream Technologies, a leading provider of augmented reality enterprise solutions, announce the...

at 10:52
Layer1 Technologies, the first U.S. based vertically-integrated and renewable energy Bitcoin mining and factory development company, announced today that it has started mining at its Bitcoin factory in West Texas. With multiple...

at 10:50
Input 1, a digital billing and payments provider to the insurance industry, is excited to announce that Western Premium Finance, LLC has selected Input 1's cloud-based Premium Billing System for its insurance premium finance business. Formed in...

at 10:45
Hoth Therapeutics, Inc.  a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne along with gene therapy treatment for asthmatics,...



News published on 21 may 2019 at 16:10 and distributed by: